Copyright
©The Author(s) 2016.
World J Cardiol. Feb 26, 2016; 8(2): 114-119
Published online Feb 26, 2016. doi: 10.4330/wjc.v8.i2.114
Published online Feb 26, 2016. doi: 10.4330/wjc.v8.i2.114
Ref. | Clinical setting | NO. of studies and of patients | Results |
Costanzo et al[26] | POAF | 8 RCTs/2687 pts | AF reduction |
Benedetto et al[27] | POAF | 431 pts | No AF reduction; at meta-regression analysis: Trend toward a benefit from PUFA for administration of EPA/DHA ratio = 1:2 |
Zhang et al[28] | POAF | 8 RCT/2687 pts | No AF reduction |
Ali-Hassan-Sayegh et al[29] | POAF | 23 RCTs/4278 pts | AF reduction |
- Citation: Martino A, Pezzi L, Magnano R, Salustri E, Penco M, Calo’ L. Omega 3 and atrial fibrillation: Where are we? World J Cardiol 2016; 8(2): 114-119
- URL: https://www.wjgnet.com//full/v8/i2/114.htm
- DOI: https://dx.doi.org/10.4330/wjc.v8.i2.114